Introduction
Colorectal cancer (CRC) is the third most common cause of death from cancer in Western Europe and North America. 1 Literature has shown the relationship between systemic chronic inflammation and various types of cancer, including CRC, 2 as the activation of the inflammatory cascade by malignant tumors leads to apoptosis inhibition and angiogenesis promotion, eventually causing tumor genesis, proliferation, and metastasis. 3, 4 In clinical practice, physicians commonly test the liver enzyme aspartate aminotransferase (AST), without evidence of any correlation with the response to bevacizumab (B).
To our knowledge, no population-based study has yet been conducted on the prognostic value of baseline AST-lymphocyte ratio index (ALRI) in predicting progression-free survival (PFS) in CRC patients treated with B. We think that the ALRI is an important parameter that provides data after combining the inflammatory state with a hepatic index.
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We investigated the prognostic and predictive roles of baseline ALRI in metastatic CRC (mCRC) patients treated with first-line chemotherapy (CT)+B or CT alone in the Phase III prospective multicenter randomized ITACa trial (Italian Trial in Advanced Colorectal Cancer; EudraCT no 2007-004539-44 and on ClinicalTrials.gov NCT01878422). 5 
Patients and methods

The iTaca trial
Patients randomly received CT+B or CT alone as first-line therapy. CT consisted of either FOLFOX4 (a 2-hour infusion of 85 mg/m 2 oxaliplatin on day 1 and a 2-hour infusion of 100 mg/m 2 leucovorin followed by 400 mg/m 2 bolus 5-FU and a 22-hour infusion of 600 mg/m 2 5-FU on days 1-2 every 2 weeks) or FOLFIRI (a 2-hour infusion of 100 mg/m 2 leucovorin followed by 400 mg/m 2 bolus 5-FU and a 22-hour infusion of 600 mg/m 2 5-FU on days 1-2 every 2 weeks with the addition of a 90-minute infusion of 180 mg/m 2 irinotecan on day 1) at the clinician's discretion. A 30-90-minute intravenous infusion of 5 mg/kg B was administered on day 1 of each 2-week cycle.
Treatment continued until either progressive disease (PD) or unacceptable toxicity or withdrawal of consent. Tumor assessment was performed before the start of treatment and repeated every 8 weeks until PD. Responses were defined according to the Response Evaluation Criteria in Solid Tumors guidelines (per investigator assessment). The National Cancer Institute Common Toxicity Criteria were used for evaluating adverse events.
The statistical analysis PFS and overall survival (OS) were, respectively, the primary and one of the secondary endpoints of the ITACa study. Information on AST and lymphocyte counts from blood tests carried out at baseline (before systemic treatment) was collected subsequently for the purpose of this post hoc analysis. ALRI was calculated as AST/lymphocyte count. The aim of this analysis was to evaluate the association between baseline ALRI levels and PFS and OS in the intent-to-treat population.
PFS was defined as the time from the date of random assignment to the date of either first documentation of PD, or last tumor evaluation, or death from any cause. Patients undergoing curative metastasectomy were censored at the date of surgery. OS was defined as the time from the date of random assignment to the date of death or last follow-up visit. PFS and OS were estimated by Kaplan-Meier method and curves were compared using the log rank test. Cox regression model was used to estimate HRs, their 2-sided 95% CI, and HR adjusted by center, baseline characteristics (gender, age, Eastern Cooperative Oncology Group performance status [ECOG PS], KRAS status, and tumor localization), CT regimen, and ITACa treatment. Cox regression model was also used to evaluate the effect on PFS and OS of the interaction between ALRI levels and treatment, including ALRI levels, treatment, and treatment-by-ALRI levels. X-tile 3.6.1 software (Yale University, New Haven, CT, USA) was used for bioinformatics analysis of baseline data to determine the cutoff value for pretreatment levels of ALRI. ALRI $14 was considered as a high level.
Patient characteristics were compared with χ 2 test, and median values were compared using nonparametric ranking test (median test). All p-values were based on 2-sided testing. Statistical analyses were performed using SAS statistical software version 9.4 (SAS Inc., Cary, NC, USA). 
Results
Patient characteristics
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Prognostic role of alri in patients with mcrc was 36 months (range 1-65). Overall, median PFS was 9.1 (95% CI 8.4-9.8) and median OS was 21.4 months (95% CI 19.9-24.5). The 2 groups of patients were comparable with regard to age, gender, tumor localization, stage at diagnosis, KRAS status, and ITACa treatment. A considerable proportion of patients with high ALRI had performance status 1-2.
alri values and clinical outcome in all patients
Considering ALRI as a continuous variable, we observed that increased ALRI levels were associated with decreased PFS (HR 1.02, 95% CI 1.01-1.02, p,0.0001) and OS (HR 1.02, 95% CI 1.02-1.03, p,0.0001).
The 2 groups of patients were comparable for all the major clinical characteristics investigated, except for EOCG and CT regimen (Table 1) .
At baseline, median PFS was 10.3 months (95% CI 9.4-12.0) and 8.0 months (95% CI 6.8-8.9) for patients with low (,14) and high ($14) ALRI levels, respectively (HR 1.43, 95% CI 1.12-1.82, p=0.004) (Figure 2A ). Median OS was 25.5 months (95% CI 21.3-30.2) and 18.8 months (95% CI 16.6-21.7) for patients with low and high baseline ALRI levels, respectively (HR 1.51, 95% CI 1.17-1.96, p,0.001) ( Figure 2B ). ALRI, AST, and lymphocyte values were associated with different toxicities (Table 2) .
Following adjustment for clinical covariates (age, gender, ECOG, tumor localization, CT regimen, KRAS status, ITACa treatment, and LDH level and liver metastasis), multivariate analysis confirmed ALRI as an independent prognostic factor for predicting PFS (HR 1.35, 95% CI 1.02-1.79, p=0.034) and OS (HR 1.35, 95% CI 1.01-1.83 p=0.048) ( Table 3 ). Considering ALRI as a continuous variable, we observed also in patients undergoing CT+ B that increased ALRI levels were associated with decreased PFS (HR 1.01, 95% CI 1.01-1.02 At baseline, median PFS was 11.3 months (95% CI 9.1-13.4) and 9.2 months (95% CI 6.8-11.3) for patients with low and high ALRI levels, respectively ( p=0.304; HR 1.20, 95% CI 0.85-1.69, p=0.304) ( Figure 3A) . On the other hand, median OS was 22.7 and 15.9 months for patients with low and high baseline ALRI, respectively (HR 1.36, 95% CI 0.95-1.96, p=0.095) ( Figure 3B At baseline, median PFS was 10.0 months (95% CI 9.0-11.8) and 7.0 months (95% CI 5.9-8.4) for patients with low and high ALRI levels, respectively ( p=0.002; HR 1.71, 95% CI 1.22-2.41, p=0.002) ( Figure 3C ). Median OS was 27.1 and 20.2 months for patients with low and high baseline ALRI levels, respectively ( p=0.007; HR 1.64, 95% CI 1.14-2.36, p=0.007) ( Figure 3D ).
Interaction tests on ALRI levels and treatment efficacy in the CT+B and CT only groups were statistically significant for PFS ( p=0.0003) but not for OS ( p=0.228). Figure 4 shows the Kaplan-Meier curves of PFS of patients treated with CT+B and CT alone with respect to ALRI levels.
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Discussion
Our study showed that high levels of ALRI at baseline were associated with shorter PFS and OS than low ALRI levels. To our knowledge, our study is the first to have assessed the prognostic value of ALRI in patients with CRC, potentially representing a noninvasive predictor of prognosis for CRC patients. However, the cutoff value of ALRI in our report was different from what was previously reported in other diseases. 6, 7 ALRI was evaluated in particular in patients with hepatocellular carcinoma, as levels of AST are higher and lymphocyte levels are lower due to cirrhosis. AST plays a role in the metabolism of amino acids in the liver, and thus its increase becomes a biochemical marker of liver failure. 8 Lymphocytes play a role in the antitumor immune response, and their presence relates to a reduced risk of relapse in several situations. 9 Increased serum AST may be a result of the progression of liver diseases, as intracellular AST is released when the hepatic parenchymal cells are injured. Conversely, decreased lymphocytes can reduce the antitumor immunity of the patients. For this reason, ALRI may be used for predicting response and OS.
B, a recombinant humanized monoclonal antibody directed against vascular endothelial growth factor, was found to improve survival in both first-and second-line settings when added to CT. 10 There is no current validated clinical or biological factor that can predict response to B. A positive result to the interaction test indicates that the ALRI index may be predictive of B efficacy. We hypothesize that B may be capable of contrasting the negative predictive value of high baseline levels of ALRI. In fact, among patients with high ALRI levels, PFS was lower in those treated with CT alone than in those treated with CT+B.
With regard to toxicity, it is noteworthy that high values of ALRI and AST were mostly associated with a higher incidence of fatigue, probably as result of a greater amount of liver disease at baseline, which may induce higher chemorelated toxicity.
In conclusion, pretreatment levels of ALRI may constitute a marker of aggressiveness in CRC patients. Elevated ALRI levels prior to treatment seem to be indicators of poor prognosis.
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